143TiPIMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC. (3rd April 2017) - Jassem, J.; de Marinis, F.; Spigel, D.R.; Lam, S.; Mocci, S.; Sandler, A.; Lopez-Chavez, A.; Deng, Y.; Giaccone, G.; Herbst, R.S.